Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RNA

Avidity Biosciences Inc

Sep 12 • 04:00PM ET

44.74

+3.70 9.02 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA VRTX SRPT ALNY IONS ARWR NBIX BLUE EXEL SGMO

| Held by: VTI IWM XBI VB VXF IWO VBR IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.56	Insider Own	9.86%	Shs Outstand	120.78M	Perf Week	-11.16%
Market Cap	5.76B	Forward P/E	-	EPS next Y	-4.88	Insider Trans	-5.23%	Shs Float	115.98M	Perf Month	-3.06%
Enterprise Value	4.58B	PEG	-	EPS next Q	-1.14	Inst Own	103.18%	Short Float	15.15%	Perf Quarter	39.20%
Income	-455.74M	P/S	536.42	EPS this Y	-54.39%	Inst Trans	3.74%	Short Ratio	5.84	Perf Half Y	39.25%
Sales	10.73M	P/B	4.53	EPS next Y	-9.38%	ROA	-33.56%	Short Interest	17.57M	Perf YTD	53.85%
Book/sh	9.87	P/C	4.86	EPS next 5Y	-6.62%	ROE	-37.76%	52W High	56.00 -20.11%	Perf Year	9.68%
Cash/sh	9.20	P/FCF	-	EPS past 3/5Y	-0.47% -34.37%	ROIC	-38.17%	52W Low	21.51 108.00%	Perf 3Y	99.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.33% 36.27%	Gross Margin	71.60%	Volatility	8.01% 5.42%	Perf 5Y	55.89%
Dividend TTM	-	EV/Sales	426.63	EPS Y/Y TTM	-20.45%	Oper. Margin	-4863.30%	ATR (14)	3.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.26	Sales Y/Y TTM	1.23%	Profit Margin	-4247.77%	RSI (14)	50.15	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	9.26	EPS Q/Q	-83.30%	SMA20	-3.38%	Beta	0.98	Target Price	68.94
Payout	-	Debt/Eq	0.00	Sales Q/Q	88.12%	SMA50	10.36%	Rel Volume	4.57	Prev Close	41.04
Employees	391	LT Debt/Eq	0.00	Earnings	Aug 07 AMC	SMA200	32.96%	Avg Volume	3.01M	Price	44.74
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.28% 158.15%	Trades		Volume	12,961,771	Change	9.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Buy	$55
Jun-24-25	Initiated	Bernstein	Outperform	$50
Jun-17-25	Initiated	Wolfe Research	Outperform	$55
Jun-11-25	Initiated	Raymond James	Strong Buy	$65
Mar-13-25	Initiated	Citigroup	Buy	$70
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$72
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$70
Dec-20-24	Initiated	H.C. Wainwright	Buy	$72
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$67
Sep-24-24	Initiated	Goldman	Buy	$59
Aug-28-24	Initiated	Barclays	Overweight	$63
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50
Jun-17-21	Initiated	Needham	Buy	$50
Apr-26-21	Resumed	Credit Suisse	Outperform	$37

Show Previous Ratings

Sep-13-25 12:01PM	Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating (Insider Monkey)
Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive) +9.02%
Sep-10-25 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire) -11.55%
07:00AM	Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44 and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44 (PR Newswire)
12:59AM	Cantor Fitzgerald Reiterates a Buy Rating on Avidity Biosciences (RNA) (Insider Monkey)
09:00AM	Loading…
Aug-27-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-25 02:23PM	RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? (Zacks)
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-13-25 08:15AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-07-25 05:10PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
10:19AM	Avidity (RNA) Gets 26% Jump on Potential Takeover (Insider Monkey)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +26.14%
12:47PM	Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal (Investor's Business Daily)
12:00PM	Loading…
12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com)
11:41AM	Novartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters)
Jul-28-25 09:39AM	Facioscapulohumeral Muscular Dystrophy Pipeline Market Insight Report 2025 \| In-depth Analysis of 10+ Companies and 12+ Pipeline Drugs (GlobeNewswire)
09:00AM	Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission (PR Newswire)
Jul-26-25 11:03AM	Avidity (RNA) Jumps 9.2% on Drug Candidate's Breakthrough Therapy Designation (Insider Monkey)
Jul-23-25 09:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Jul-13-25 06:15AM	Raymond James Predicts Up to ~760% Surge for These 2 Strong Buy Stocks (TipRanks)
Jun-11-25 08:03PM	Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James (Insider Monkey)
09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
09:00AM	Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress (PR Newswire)
Jun-10-25 09:25AM	Avidity Biosciences price target raised to $75 from $65 at Chardan (TipRanks)
Jun-09-25 02:04PM	Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial (Benzinga) -9.88%
07:01AM	Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants (PR Newswire)
07:00AM	Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD Study in FSHD (PR Newswire)
May-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
05:55PM	Loading…
May-08-25 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +9.63%
04:05PM	Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
May-06-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire) -18.65%
Apr-24-25 05:15PM	Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates (Zacks)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +6.98%
04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-08-25 09:00AM	Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire) -5.49%
Apr-05-25 05:22PM	Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks) -5.61%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.42%
09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Mar-31-25 09:00AM	Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire) -6.58%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.98%
Mar-17-25 07:00AM	Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44 Trial (PR Newswire) +8.74%
Mar-12-25 04:05PM	Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire) +10.24%
Feb-28-25 09:00AM	Avidity Biosciences Honors Rare Disease Day and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases (PR Newswire) +5.36%
Feb-27-25 05:40PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
Feb-25-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-20-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-17-25 11:06AM	Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-08-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire)
Jan-01-25 01:12PM	Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now? (Insider Monkey)
Dec-20-24 05:00PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-26-24 10:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Nov-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-13-24 04:07PM	Avidity Bio Has Surged 416% This Year And That's Before Today's 'Game-Changing' News (Investor's Business Daily) +12.35%
Nov-12-24 07:00AM	Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations (PR Newswire)
Nov-07-24 06:10PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
Nov-06-24 10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:27AM	An RNAi renaissance is creating a new generation of startups (BioPharma Dive)
Oct-31-24 09:00AM	Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 (PR Newswire)
Oct-30-24 08:00AM	Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
Oct-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.41%
Oct-18-24 08:00AM	Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up (Investor's Business Daily)
Oct-04-24 07:00PM	Why Avidity Biosciences Zoomed to a 12% Gain This Week (Motley Fool) -7.08%
10:53AM	FDA lifts clinical hold on Aviditys lead antibody conjugate therapy trial (Pharmaceutical Technology)
Oct-03-24 07:00AM	Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) (PR Newswire)
Sep-29-24 06:27AM	Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024? (Insider Monkey)
Sep-26-24 07:34PM	Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey) -8.23%
Sep-25-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Sep-23-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-05-24 09:00AM	Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month (PR Newswire)
Aug-28-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-20-24 07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
Aug-19-24 09:00AM	Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Aug-14-24 08:30PM	Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +6.16%
Aug-13-24 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire)
Aug-09-24 08:53PM	RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace) +12.13% -5.26%
05:20PM	Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:17PM	How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics (Investor's Business Daily)
04:05PM	Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
07:00AM	Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial (PR Newswire)
Aug-05-24 09:15AM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer (PR Newswire)
Jul-24-24 06:41AM	3 Stocks Doing Even Better Than Superstar Super Micro (SMCI) (InvestorPlace)
Jul-23-24 07:00AM	3 Russell 2000 Growth Stocks That Could Be Worth the Risk (Motley Fool)
Jul-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-03-24 06:53AM	Aviditys FSHD drug del-brax shows promise in Phase I/II trial (Clinical Trials Arena)
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-24 09:00AM	Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day (PR Newswire)
Jun-17-24 04:05PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Sep 12 04:07 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Sale	38.94	20,000	778,702	80,195	Sep 12 04:07 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 11 '25	Proposed Sale	46.40	20,000	928,000		Sep 11 04:24 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Option Exercise	12.48	14,500	180,960	83,925	Sep 09 05:53 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Sale	50.00	29,500	1,475,000	54,425	Sep 09 05:53 PM
Boyce Sarah	President and CEO	Sep 05 '25	Option Exercise	1.24	50,000	62,000	355,871	Sep 05 06:56 PM
Boyce Sarah	President and CEO	Sep 05 '25	Sale	49.95	50,000	2,497,435	305,871	Sep 05 06:56 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Option Exercise	9.05	6,563	59,395	61,563	Sep 05 06:32 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Sale	47.07	6,563	308,936	55,000	Sep 05 06:32 PM
SARAH BOYCE	Director	Sep 05 '25	Proposed Sale	48.47	50,000	2,423,500		Sep 05 04:25 PM
WILSON TROY EDWARD	Chairman	Sep 05 '25	Proposed Sale	50.00	95,052	4,752,600		Sep 05 04:10 PM
ERIC MOSBROOKER	Officer	Sep 03 '25	Proposed Sale	47.23	19,688	929,864		Sep 03 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Sep 02 '25	Sale	47.42	188	8,915	50,204	Sep 02 08:30 PM
Boyce Sarah	President and CEO	Aug 28 '25	Option Exercise	1.24	25,000	31,000	330,871	Aug 29 04:28 PM
Boyce Sarah	President and CEO	Aug 28 '25	Sale	49.39	25,000	1,234,700	305,871	Aug 29 04:28 PM
SARAH BOYCE	Director	Aug 28 '25	Proposed Sale	47.82	25,000	1,195,500		Aug 28 04:21 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Aug 22 05:20 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Sale	46.40	2,208	102,462	38,867	Aug 22 05:20 PM
McCarthy Teresa	Chief Human Resources Officer	Aug 15 '25	Option Exercise	22.34	10,000	223,400	107,130	Aug 15 05:50 PM
McCarthy Teresa	Chief Human Resources Officer	Aug 15 '25	Sale	46.56	10,000	465,632	97,130	Aug 15 05:50 PM
TERESA MCCARTHY	Officer	Aug 15 '25	Proposed Sale	46.07	45,000	2,073,150		Aug 15 04:27 PM
MacLean Michael F	Chief Financial Officer	Aug 06 '25	Sale	42.73	30,914	1,320,844	65,806	Aug 15 04:09 PM
Hughes Steven George	Chief Medical Officer	Aug 13 '25	Option Exercise	6.57	1,542	10,131	40,409	Aug 15 04:07 PM
Hughes Steven George	Chief Medical Officer	Aug 13 '25	Sale	46.66	1,542	71,950	38,867	Aug 15 04:07 PM
STEVEN GEORGE HUGHES	Officer	Aug 13 '25	Proposed Sale	46.23	9,709	448,847		Aug 13 04:31 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Option Exercise	9.05	124,687	1,128,417	185,807	Aug 08 05:45 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Sale	44.06	130,807	5,763,697	55,000	Aug 08 05:45 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Option Exercise	12.14	29,500	358,260	91,425	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	65,554	2,949,930	17,776	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	29,500	1,327,500	69,425	Aug 08 05:42 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Option Exercise	22.34	107,500	2,401,550	127,150	Aug 08 05:41 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Sale	47.62	107,500	5,118,881	19,650	Aug 08 05:41 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Option Exercise	12.21	47,451	579,180	90,517	Aug 08 05:39 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Sale	42.74	81,434	3,480,269	38,867	Aug 08 05:39 PM
ERIC MOSBROOKER	Officer	Aug 06 '25	Proposed Sale	38.26	130,807	5,004,676		Aug 06 04:23 PM
STEVEN GEORGE HUGHES	Officer	Aug 06 '25	Proposed Sale	38.26	81,434	3,115,665		Aug 06 04:23 PM
ARTHUR LEVIN	Director	Aug 06 '25	Proposed Sale	38.26	107,500	4,112,950		Aug 06 04:23 PM
MICHAEL MACLEAN	Officer	Aug 06 '25	Proposed Sale	38.26	30,914	1,182,770		Aug 06 04:22 PM
WILSON TROY EDWARD	Chairman	Aug 06 '25	Proposed Sale	45.00	95,054	4,277,430		Aug 06 04:08 PM
Moriarty John B	Chief Legal Officer	Aug 04 '25	Sale	36.21	2,245	81,291	47,755	Aug 05 05:27 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 17 '25	Sale	30.24	911	27,549	50,392	Jun 18 06:02 PM
KATHLEEN GALLAGHER	Officer	Jun 17 '25	Proposed Sale	29.80	911	27,148		Jun 17 04:19 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Jun 12 06:18 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Sale	32.88	20,000	657,694	80,195	Jun 12 06:18 PM
WILLIAM MICHAEL FLANAGAN	Officer	Jun 11 '25	Proposed Sale	33.62	20,000	672,400		Jun 11 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Option Exercise	16.65	5,875	97,819	56,429	Jun 04 04:48 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Sale	32.48	5,875	190,833	50,554	Jun 04 04:48 PM
KATHLEEN GALLAGHER	Officer	Jun 02 '25	Proposed Sale	30.98	5,875	182,008		Jun 02 04:37 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Option Exercise	16.65	5,875	97,819	56,429	May 02 07:55 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Sale	32.40	5,875	190,324	50,554	May 02 07:55 PM
KATHLEEN GALLAGHER	Officer	May 01 '25	Proposed Sale	32.65	5,875	191,819		May 01 04:57 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Option Exercise	14.81	5,875	87,004	56,100	Apr 03 04:56 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Sale	27.83	5,875	163,486	50,554	Apr 03 04:56 PM
Hughes Steven George	Chief Medical Officer	Mar 20 '25	Sale	31.06	9,578	297,491	72,850	Mar 21 06:44 PM
Boyce Sarah	President and CEO	Mar 20 '25	Sale	31.06	31,540	979,563	305,871	Mar 21 06:42 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 20 '25	Sale	31.06	11,780	365,868	80,195	Mar 21 06:40 PM
MacLean Michael F	Chief Financial Officer	Mar 20 '25	Sale	31.06	7,935	246,425	96,720	Mar 21 06:38 PM
McCarthy Teresa	Chief Human Resources Officer	Mar 20 '25	Sale	31.06	7,778	241,583	97,130	Mar 21 06:36 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 11 '25	Option Exercise	14.22	20,000	284,400	111,975	Mar 12 04:23 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 11 '25	Sale	30.13	20,000	602,614	91,975	Mar 12 04:23 PM
WILLIAM MICHAEL FLANAGAN	Officer	Mar 11 '25	Proposed Sale	30.04	20,000	600,800		Mar 11 04:35 PM
Gallagher Kathleen P.	Chief Program Officer	Mar 03 '25	Option Exercise	14.70	5,875	86,362	56,429	Mar 04 06:17 PM
Gallagher Kathleen P.	Chief Program Officer	Mar 03 '25	Sale	29.41	5,875	172,807	50,554	Mar 04 06:17 PM
Gallagher Kathleen P.	Chief Program Officer	Feb 03 '25	Option Exercise	16.65	5,875	97,819	56,429	Feb 05 05:01 PM
Gallagher Kathleen P.	Chief Program Officer	Feb 03 '25	Sale	32.16	5,875	188,918	50,554	Feb 05 05:01 PM
KATHLEEN GALLAGHER	Officer	Feb 03 '25	Proposed Sale	32.93	17,625	580,391		Feb 03 04:34 PM
LEVIN ARTHUR A	Director	Jan 21 '25	Sale	28.60	1,872	53,537	12,958	Jan 23 08:17 PM
MacLean Michael F	Chief Financial Officer	Jan 21 '25	Sale	28.59	3,287	93,985	104,655	Jan 23 08:15 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 21 '25	Sale	28.59	2,959	84,612	104,908	Jan 23 08:14 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 21 '25	Sale	28.60	5,672	162,192	91,975	Jan 23 08:12 PM
Boyce Sarah	President and CEO	Jan 21 '25	Sale	28.59	10,397	297,291	337,411	Jan 23 08:10 PM
Gallagher Kathleen P.	Chief Program Officer	Jan 22 '25	Sale	30.16	5,629	169,776	50,554	Jan 23 08:08 PM
Gallagher Kathleen P.	Chief Program Officer	Jan 21 '25	Sale	28.59	3,782	108,136	56,183	Jan 23 08:08 PM
Hughes Steven George	Chief Medical Officer	Jan 21 '25	Sale	28.59	3,947	112,856	82,428	Jan 23 08:06 PM
KATHLEEN GALLAGHER	Officer	Jan 22 '25	Proposed Sale	30.84	6,924	213,536		Jan 22 04:25 PM
Flanagan W. Michael	CSTO	Dec 18 '24	Sale	32.66	12,742	416,154	72,647	Dec 19 06:17 PM
MacLean Michael F	Chief Financial Officer	Dec 18 '24	Sale	32.66	11,151	364,192	82,942	Dec 19 06:16 PM
Boyce Sarah	President and CEO	Dec 18 '24	Sale	32.66	31,855	1,040,384	265,308	Dec 19 06:15 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 18 '24	Sale	32.66	11,151	364,192	82,867	Dec 19 06:15 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 16 '24	Option Exercise	14.22	25,000	355,500	119,018	Dec 18 04:46 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 16 '24	Sale	33.26	25,000	831,605	94,018	Dec 18 04:46 PM
TERESA MCCARTHY	Officer	Dec 16 '24	Proposed Sale	32.49	25,000	812,250		Dec 16 04:29 PM
Flanagan W. Michael	CSTO	Dec 11 '24	Option Exercise	22.47	24,000	539,280	109,389	Dec 13 06:08 PM
Flanagan W. Michael	CSTO	Dec 11 '24	Sale	35.77	24,000	858,401	85,389	Dec 13 06:08 PM
W. MICHAEL FLANAGAN	Officer	Dec 11 '24	Proposed Sale	36.10	24,000	866,400		Dec 11 04:59 PM
McCarthy Teresa	Chief Human Resources Officer	Nov 18 '24	Option Exercise	14.22	25,000	355,500	119,018	Nov 20 06:10 PM
McCarthy Teresa	Chief Human Resources Officer	Nov 18 '24	Sale	41.14	25,000	1,028,520	94,018	Nov 20 06:10 PM
LEVIN ARTHUR A	Director	Nov 19 '24	Option Exercise	1.24	3,323	4,121	18,153	Nov 20 06:06 PM
LEVIN ARTHUR A	Director	Nov 19 '24	Sale	42.12	3,323	139,973	14,830	Nov 20 06:06 PM
MacLean Michael F	Chief Financial Officer	Nov 06 '24	Option Exercise	8.43	79,057	666,064	159,275	Nov 08 04:50 PM
MacLean Michael F	Chief Financial Officer	Nov 06 '24	Sale	45.56	106,319	4,843,979	94,093	Nov 08 04:50 PM
MICHAEL MACLEAN	Officer	Nov 06 '24	Proposed Sale	45.09	106,319	4,793,924		Nov 06 04:56 PM
LEVIN ARTHUR A	Director	Oct 21 '24	Option Exercise	1.24	5,000	6,200	19,830	Oct 23 04:19 PM
LEVIN ARTHUR A	Director	Oct 21 '24	Sale	46.63	5,000	233,168	14,830	Oct 23 04:19 PM
ARTHUR A LEVIN	Director	Oct 21 '24	Proposed Sale	50.45	8,323	419,895		Oct 21 04:21 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 16 '24	Option Exercise	14.22	25,000	355,500	119,018	Oct 17 04:20 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 16 '24	Sale	48.52	25,000	1,213,010	94,018	Oct 17 04:20 PM
LEVIN ARTHUR A	Officer	Oct 16 '24	Proposed Sale	46.60	22,500	1,048,500		Oct 16 01:48 PM
Thompson Tamar	Director	Oct 07 '24	Option Exercise	27.63	30,000	828,900	30,000	Oct 09 05:23 PM
Thompson Tamar	Director	Oct 07 '24	Sale	44.98	30,000	1,349,259	0	Oct 09 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNA

Avidity Biosciences Inc

Upgrade your FINVIZ experience